RFK Jr.’s vaccine panel to vote on hepatitis B shot for babies

Upcoming Vote on Hepatitis B Vaccine Recommendation Sparks Concerns

A crucial vote is scheduled to take place on Thursday regarding the hepatitis B vaccine recommendation for newborns. The Advisory Committee on Immunization Practices (ACIP) will decide whether to alter the long-standing guideline that every baby should receive the vaccine within 24 hours of birth. This decision has significant implications, as hepatitis B can lead to liver disease and early death, with no cure available.

The current recommendation, introduced in 1991, has been instrumental in reducing infections in children by 99%. Public health experts, such as Neil Maniar, a professor at Northeastern University, emphasize the importance of maintaining this guideline. “We have a vaccine that is highly effective at preventing an incurable disease. We should take full advantage of that,” Maniar stated. Any changes to the recommendation could lead to an increase in chronic infections among children, which would be a significant setback in the fight against this disease.

Background and Context

The hepatitis B vaccine is typically administered to newborns to prevent the transmission of the virus from mother to child during childbirth. The vaccine has been proven to be highly effective, with a remarkable success story of reducing infections in kids by 99% since its introduction. The American Academy of Pediatrics (AAP) still recommends the universal birth dose of the hepatitis B vaccine, citing its life-saving benefits.

A recent review of over 400 studies spanning four decades found no evidence that delaying the universal hepatitis B vaccine birth dose improves safety or effectiveness. In fact, the review concluded that the birth dose does not cause any short- or long-term serious adverse events or deaths. This reinforces the importance of maintaining the current recommendation to ensure the continued protection of newborns against this serious disease.

Potential Consequences and Concerns

Any changes to the recommendation could have far-reaching consequences, including potential vaccine supply disruptions. John Grabenstein, a former Merck vaccine executive, warned that altering the recommendation without warning could lead to spot shortages, as manufacturers have built up their reserves and calculations based on the current demand. Grabenstein’s primary concern, however, is that fewer children will receive the vaccine on time, leaving them vulnerable to infection.

Merck, one of the manufacturers of the hepatitis B vaccine, has also expressed concerns about changing the recommendation. Dr. Richard Haupt, Merck’s head of global medical and scientific affairs for vaccines and infectious diseases, stated that reconsidering the newborn hepatitis B vaccination schedule poses a grave risk to the health of children and the public, which could lead to a resurgence of preventable infectious diseases.